Ginkgo Bioworks Holdings Inc (DNA) concluded trading on Wednesday at a closing price of $9.11, with 3.94 million shares of worth about $35.85 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 11.78% during that period and on Wednesday the price saw a loss of about -11.47%. Currently the company’s common shares owned by public are about 41.37M shares, out of which, 36.50M shares are available for trading.
Stock saw a price change of -28.15% in past 5 days and over the past one month there was a price change of -22.93%. Year-to-date (YTD), DNA shares are showing a performance of -7.23% which decreased to -82.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.26 but also hit the highest price of $64.40 during that period. The average intraday trading volume for Ginkgo Bioworks Holdings Inc shares is 1.61 million. The stock is currently trading -28.83% below its 20-day simple moving average (SMA20), while that difference is down -19.84% for SMA50 and it goes to -25.20% lower than SMA200.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) currently have 41.37M outstanding shares and institutions hold larger chunk of about 58.55% of that.
The stock has a current market capitalization of $523.63M and its 3Y-monthly beta is at 1.20. It has posted earnings per share of -$12.90 in the same period. It has Quick Ratio of 5.79 while making debt-to-equity ratio of 0.56. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DNA, volatility over the week remained 14.48% while standing at 14.26% over the month.
Stock’s fiscal year EPS is expected to rise by 37.25% while it is estimated to increase by 36.44% in next year.
Stock get a Sell rating from Goldman on June 02, 2023.
